<DOC>
	<DOCNO>NCT02202616</DOCNO>
	<brief_summary>This single cohort , prospective post approval study conduct patient COPD Canada . The study enroll patient respond current treatment tiotropium alone , fix dose combination fluticasone propionate/salmeterol . Only patient physician decide change treatment due lack efficacy eligible enrol study . Also evaluate real-life effectiveness QVA149 ( indacaterol 110 mcg/glycopyrronium 50 mcg ) management patient .</brief_summary>
	<brief_title>Prospective Cohort Study Real - Life Effectiveness Evaluation GlycOpyrronium With IndacatERol Combination Management COPD Canada ( POWER Study )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patient diagnose treated moderate severe COPD accord Global Initiative Chronic Obstructive Lung Disease accord physician 's assessment Smoking history &gt; 10 pack year . Ongoing treatment tiotropium fix dose combination LABA/ICS , specifically combination fluticasone propionate/salmeterol minimum three month demonstrate persistence symptom indicate change treatment combination therapy **using CAT score &gt; 10 . Treatment QVA149 indicate per product monograph appropriate patient per judgment treat physician . Patient sign informed consent agree participate study undergo study treatment allow use data purpose study . Patient expect available 16 week study enrolment Assessed per routine care document patient 's chart . ** As determine decide treat physician prior enrolment patient study . Patients fulfil follow criterion eligible inclusion study . No additional exclusion may apply investigator , order ensure study population representative eligible patient . Patients willing sign inform consent . Patient maintenance treatment include triple therapy ( LABA +LAMA+ICS ) COPD Patients diagnosis asthma history asthma . Patients two moderate severe exacerbation last 12 month prior study enrolment . A moderate COPD exacerbation define requirement treatment systemic corticosteroid antibiotic . A severe COPD exacerbation define hospitalization , include emergency room visit longer 24 h. Patients exacerbation within previous 6 week enrolment . Patients per physician clinical judgment require ICS treatment coadministered QVA149 study period . Patients chronic respiratory condition may affect outcome treatment include limited lung cancer .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD ,</keyword>
	<keyword>QVA149 ,</keyword>
	<keyword>Tiotropium ,</keyword>
	<keyword>FDC ,</keyword>
	<keyword>GlycOpyrronium With IndacatERol ,</keyword>
	<keyword>POWER</keyword>
</DOC>